Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Myotonic dystrophy type 1 (DM1) is a complex, multisystemic neuromuscular disorder.
• DM1 presents challenges in clinical management due to its widespread effects beyond skeletal muscle.
• Delayed diagnosis and varied manifestations complicate patient care.

Purpose of the Study:

• To review multisystem symptoms of DM1.
• To discuss current treatments and novel disease-modifying therapies for DM1.
• To explore therapies targeting DM1's molecular mechanisms for improved patient outcomes.

Main Methods:

• Review of existing literature on DM1 symptoms and treatments.
• Exploration of emerging therapeutic strategies including antisense oligonucleotides (ASOs), small molecules, and gene editing.
• Analysis of how understanding DM1's molecular mechanisms informs therapy development.

Main Results:

• Current management relies on symptom-specific strategies like physical therapy, myotonia medications, cardiac care, and metabolic/hormonal therapies.
• Promising targeted therapies are emerging, including ASOs for RNA degradation.
• Small molecules and gene editing offer prospective approaches to DM1's underlying mechanisms.

Conclusions:

• A comprehensive approach is needed for DM1, addressing its multisystemic nature.
• Novel therapies targeting molecular mechanisms hold promise for improving patient outcomes and quality of life.
• Continued research into DM1 pathogenesis and therapeutic interventions is crucial.